ArticleCurrent medical science2025
ESE-1 Regulates CREB-Mediated PTEN Expression to Activate the PI3K/Akt Pathway and Promote High-Glucose-Induced Endothelial Cell Injury.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveEndothelial dysfunction is a central contributor to the vascular complications observed in individuals with diabetes. cAMP response element-binding protein (CREB) plays a crucial role in mediating hyperglycemia-induced endothelial dysfunction. Phosphatase and tensin homolog (PTEN) has been implicated in the regulation of endothelial inflammation, yet the precise mechanism by which CREB modulates PTEN to protect endothelial cells under high glucose conditions remains unknown. This study aims to elucidate this potential mechanism.
methodsHuman umbilical vein endothelial cells (HUVECs) were exposed to high glucose (30 mM) or normal glucose (5.5 mM) for 6 days. Cell viability and apoptosis were assessed via the Cell Counting Kit-8 and flow cytometry. To evaluate oxidative stress, the levels of reactive oxygen species (ROS), lactate dehydrogenase (LDH), and malondialdehyde (MDA) were measured via commercial assay kits. The interaction between CREB and endothelial specific molecule 1 (ESE-1) was assessed via coimmunoprecipitation. Chromatin immunoprecipitation and luciferase reporter assays were used to investigate the transcriptional regulation of PTEN by ESE-1 and CREB. Western blotting was performed to analyze the expression of intercellular adhesion molecule-1 and E-selectin. The adhesion of HUVECs was evaluated via monocyte‒endothelial cell adhesion assays.
resultsOur findings revealed a direct interaction between CREB and ESE-1, which together regulate PTEN expression to activate the phosphoinositide 3-kinase/protein kinase B pathway. Under high-glucose conditions, we observed significant increases in oxidative stress, inflammatory responses, and adhesion in HUVECs. ESE-1 knockdown reversed these effects, restoring endothelial cell function. Moreover, the overexpression of PTEN in high glucose-treated HUVECs rescued the endothelial injury induced by ESE-1 knockdown, suggesting that PTEN plays a pivotal role in mediating the protective effects.
conclusionESE-1, through the regulation of CREB-mediated PTEN expression, activates the PI3K/AKT pathway and modulates key processes such as oxidative stress, inflammation, and adhesion in endothelial cells under high-glucose stress.
Indexed as
Identifiers
40956491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.